Key result
Multimodality non-invasive imaging aids early detection and targeted therapies in cardiometabolic disease.
Multiorgan imaging holds promise for tracking the pathophysiology and therapeutic response in cardiometabolic disease.
Should not yet change practice; leaves open prospective trials validating multimodality imaging in cardiometabolic disease.
Cardiometabolic disease, spanning conditions such as obesity to type 2 diabetes mellitus with excess cardiovascular risk, represents a major public health burden. Advances in preclinical translational science point to potential targets across multiple organ systems for early intervention to improve cardiometabolic health. Validation in clinical trials and translation to care would benefit from in vivo diagnostic techniques that facilitate therapeutic advancements. This review provides a state-of-the-art, multimodality perspective spanning the multiple organ systems that contribute to cardiometabolic disease.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2017) conducted a review in Cardiometabolic disease. Multimodality Imaging was evaluated. Advances in non-invasive multimodality imaging across multiple organ systems may facilitate early detection and therapeutic advancements in cardiometabolic disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: